Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics has entered into an accelerated share repurchase program with Bank of America to buy back $50 million of its common stock.

Under the terms of the agreement, Myriad will repurchase shares of its common stock discounted to the volume-weighted average share price on Nov. 16 equaling $50 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.